The Challenge of Selecting Patients with Diffuse Large-Based Cell Lymphoma Who Could Benefit Most from Clinical Trials
Jelena Jelicic highlighted the main data from the Danish study compared the International Prognostic Indices (IPI, aaIPI, NCCN-IPI) used to identify trial-eligible HI and H-risk DLBCL patients and the prognostic ability in trial-eligible patients aged ≤60. She also highlights a couple of other studies that try to analyze the impact of prognostic models as selection criteria for identifying high-risk candidates for clinical trials.
